N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.364 NOK -3.9%
Market Cap: 772m NOK

Wall Street
Price Targets

NYKD Price Targets Summary
Nykode Therapeutics ASA

Wall Street analysts forecast NYKD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NYKD is 5.44 NOK with a low forecast of 2.525 NOK and a high forecast of 8.925 NOK.

Lowest
Price Target
2.525 NOK
7% Upside
Average
Price Target
5.44 NOK
130% Upside
Highest
Price Target
8.925 NOK
278% Upside
Nykode Therapeutics ASA Competitors:
Price Targets
VRTX
Vertex Pharmaceuticals Inc
4% Upside
RNAC
Cartesian Therapeutics Inc
231% Upside
NBIX
Neurocrine Biosciences Inc
49% Upside
SNDX
Syndax Pharmaceuticals Inc
166% Upside
ONCO
Oncopeptides AB
151% Upside
BPMC
Blueprint Medicines Corp
49% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
40% Upside
CDMO
Avid Bioservices Inc
2% Upside

Revenue
Forecast

Revenue Estimate
Nykode Therapeutics ASA

For the last 7 years the compound annual growth rate for Nykode Therapeutics ASA's revenue is 110%. The projected CAGR for the next 3 years is -58%.

110%
Past Growth
-58%
Estimated Growth
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Nykode Therapeutics ASA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Nykode Therapeutics ASA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NYKD's stock price target?
Price Target
5.44 NOK

According to Wall Street analysts, the average 1-year price target for NYKD is 5.44 NOK with a low forecast of 2.525 NOK and a high forecast of 8.925 NOK.

What is Nykode Therapeutics ASA's Revenue forecast?
Projected CAGR
-58%

For the last 7 years the compound annual growth rate for Nykode Therapeutics ASA's revenue is 110%. The projected CAGR for the next 3 years is -58%.

Back to Top